Gilder Gagnon Howe & Co. LLC bought a new position in shares of Athenex, Inc. (NASDAQ:ATNX) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 89,026 shares of the company’s stock, valued at approximately $1,559,000. Gilder Gagnon Howe & Co. LLC owned 0.16% of Athenex at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Bank of New York Mellon Corp bought a new position in Athenex during the second quarter worth $240,000. Tudor Investment Corp ET AL bought a new position in Athenex during the second quarter worth $320,000. Goldman Sachs Group Inc. bought a new position in Athenex during the second quarter worth $601,000. California Public Employees Retirement System bought a new position in Athenex during the second quarter worth $800,000. Finally, Vanguard Group Inc. bought a new position in Athenex during the second quarter worth $800,000. 1.28% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/16/gilder-gagnon-howe-co-llc-takes-position-in-athenex-inc-atnx.html.

Athenex, Inc. (NASDAQ:ATNX) opened at $17.20 on Thursday. Athenex, Inc. has a 52-week low of $11.21 and a 52-week high of $20.79.

Athenex (NASDAQ:ATNX) last released its earnings results on Monday, August 14th. The company reported ($0.88) earnings per share (EPS) for the quarter. The business had revenue of $4.60 million for the quarter. equities analysts expect that Athenex, Inc. will post -2.75 earnings per share for the current year.

A number of equities analysts recently issued reports on the stock. J P Morgan Chase & Co assumed coverage on shares of Athenex in a research report on Wednesday, October 18th. They set a “neutral” rating and a $22.20 target price on the stock. Laidlaw assumed coverage on shares of Athenex in a research report on Tuesday, September 19th. They set a “buy” rating and a $36.00 target price on the stock. Credit Suisse Group assumed coverage on shares of Athenex in a research report on Monday, September 18th. They set an “outperform” rating and a $25.00 target price on the stock. Finally, Royal Bank Of Canada assumed coverage on shares of Athenex in a research report on Thursday, September 14th. They set an “outperform” rating and a $35.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $27.64.

About Athenex

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Institutional Ownership by Quarter for Athenex (NASDAQ:ATNX)

Receive News & Stock Ratings for Athenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc. and related stocks with our FREE daily email newsletter.